Nona Biosciences的动态

#TCR discovery and assay development for #Tcells targeting solid cancers Recent advances in #geneticengineering have enabled the modification #Tcellreceptors (TCRs) to target tumor-specific #antigens. Unlike #CARTcelltherapies, TCR-based therapies can target #intracellularantigens, opening a door to treating solid tumors. However, immune escape and toxicity remain significant challenges. Next month, Miltenyi Biotec’s Marc Schuster (Group Leader, R&D) and Marek Wieczorek (Scientific Director, R&D) will cover the latest approaches to identify tumor-specific TCRs and develop the corresponding robust #assays for in-process control, #QC, and #immunemonitoring. Register for this #webinar below:

Remove the guesswork from circulating tumor cell ernumeration: https://lnkd.in/gcrNcy7i Our new validated antibodies for use with the Genesis System and Celselect Slides? Enumeration Direct and Indirect Stain Kits provide sensitive and specific immunostaining of CTC surface biomarkers. #CTCEnumeration #CancerResearch #BioRadGenesis

#TCR discovery and assay development for #Tcells targeting solid cancers Recent advances in #geneticengineering have enabled the modification #Tcellreceptors (TCRs) to target tumor-specific #antigens. Unlike #CARTcelltherapies, TCR-based therapies can target #intracellularantigens, opening a door to treating solid tumors. However, immune escape and toxicity remain significant challenges. This month, Miltenyi Biotec’s Marc Schuster (Group Leader, R&D) and Marek Wieczorek (Scientific Director, R&D) will cover the latest approaches to identify tumor-specific TCRs and develop the corresponding robust #assays for in-process control, #QC, and #immunemonitoring. Register for this #webinar below:

Check out this interesting study from our premier supplier ichorbio Want to find out more: DM or contact us https://lnkd.in/dhm64Uh9 View the product here https://lnkd.in/eH6CkfFt #antibodies #antibody #oncologyresearch #RMP114 #cancerresearch #invivoantibodies #lifesciences #biosciences

ichorbio's RMP1-14 compared to the industry standard A recent study reveals that ichorbio's RMP1-14 antibody product code ICH1132 is a viable alternative to BE0146: https://lnkd.in/ep6ZFr4S "Our comparative study has shown some interesting trends for ICH1132, particularly in the early stages of tumor growth inhibition. While the differences weren't maintained throughout the entire study period, the consistent trend towards slightly higher efficacy is noteworthy. We're interested in seeing how ICH1132 performs across different research settings and how it might contribute to more refined experimental protocols." Dr. Elaine Zhang, Lead Researcher #rmp1-14 #CancerResearch #InnovationInScience #invivoantibodies

The identification of variants and biomarkers is crucial in guiding treatment decisions, as demonstrated by our co-founder and managing director, Dr. Dr. Saskia Biskup, in this patient. The patient was diagnosed with metastatic epithelioid sarcoma and underwent several resections, chemotherapies, and immunotherapies, and lastly, the inhibitor Pazopanib as the tumor progressed. The most significant finding of this tumor is the loss of ????????????1. This finding indicated the need for an EZH2 inhibitor. Learn how this finding changed the treatment approach for this patient. For more information, please take a look at?our website: https://lnkd.in/eNHeb_2P #genetics #diagnostics #tumor #tumordiagnostics

I'm happy to share my latest research abstract published in the American Gastroenterological Association (AGA) journal: "Radiofrequency Ablation in Combination with an Anti-PDL1 Checkpoint Inhibitor Reduces Tumor Growth and Enhances Anti-Tumor Immunity in a Syngeneic Model of PDAC" The abstract presents preliminary findings on a novel combination therapy for pancreatic ductal adenocarcinoma (PDAC). We investigated how radiofrequency ablation (RFA) combined with anti-PDL1 checkpoint inhibitors affects tumor growth and anti-tumor immune responses. These initial results suggest new possibilities for potentially more effective treatments in pancreatic cancer, combining local tumor destruction with immune system activation. I'm grateful to my co-authors: Lincoln Strickland, Nicolette R. Mardik, Curtis J. Wray, Nirav Thosani, and Jennifer M. Bailey-Lundberg. #CancerResearch #Gastroenterology #Immunotherapy #PDAC #AGAJournal

?? Transgene is proud to present a poster at the Oncolytic Virotherapy Conference (#IOVC2024) describing preclinical data about a novel oncolytic virus #TG7010, encoding #IL12. #TG7010 demonstrates superior tumor lytic capacity, higher dissemination into the tumors and its ability to be delivered intravenously. Various preclinical experiments show potent antitumor effects. Moreover, #TG7010, in combination with #antiPD1 treatment, demonstrated synergistic effect. Title of the poster: “TG7010: a Novel Chimeric Oncolytic Poxvirus Expressing IL-12 with Improved Properties for Systemic Delivery” ??poster ?? https://t.ly/oZpYJ Johann Foloppe, #JulietteKempf, #IsabelleFarine, Laurine Gault, Julie Hortelano, Baptiste Moreau, #MichelleKlein, Sandrine Cochin, Eric Quéméneur, Philippe Erbs. #immunotherapies #vector

New research reveals that PD-L1 plays a crucial role in tumor proliferation and immune suppression in NF2-associated meningiomas. By downregulating PD-L1, scientists observed reduced tumor growth and enhanced T-cell function, with the PI3K–AKT–mTOR pathway being key in regulating PD-L1 expression. These findings suggest that targeting PD-L1, especially in combination with mTOR inhibitors, could offer promising new treatment strategies for NF2 patients. Read the full article for more insights: https://buff.ly/3RW1kov

Unlock Your Mind: Dive into Our Quiz Challenge! ?? ?? Which signaling molecule is crucial for T-cell activation and proliferation? A) Interferon B) Interleukin-2 (IL-2) C) Tumor necrosis factor alpha (TNF-alpha) D) Transforming growth factor beta (TGF-beta) Comment with your chosen answer! #KnowledgeChallenge #Quiz